Ravens Pass on Crosby: Medical Concerns Trump Trade Hype

0:00On March 25, a new report sheds light on why the Baltimore Ravens backed out of a potential trade for Las Vegas Raiders' defensive end, Max Crosbyn. The deal involved two first round draft picks, but Ravens' doctors flagged a degenerative issue in Crosby's knee after reviewing his medical records. Sources say the team worried about his long-term durability beyond a couple of seasons. Medical experts agreed Crosbyn could return to play as early as 2026, but the bigger question was whether he could hold up for the full, value of such a high-stakes swap. Earlier this year, Crosbyn had knee surgery in January, and with a hefty contract on the table, the Ravens needed assurance he would justify the investment over multiple years. NFL teams treat degenerative knee problems as major red flags, drawing parallels to cases like Calvin Johnson, who retired early because of similar. Player and tear. Players often struggle with practice time, and face bone-on-bone contact since knee cartilage doesn't regenerate. That uncertainty makes executives think twice before

1:04committing big draft capital. Meanwhile, the Ravens pivoted to a more affordable option, citing Trey Hendrickson to a four-year deal worth $28 million a front. For the Raiders, the talks might have aligned with their own plans the Crosbyn on Crosbyn's value before his prime window closes. This insight explains the failed deal without the usual drama, highlighting how medical realities often trump trade hype in the league. That's the story for today. NFL News Today, driven by AI, I'm Cory with the Story.